Intrust Bank NA Has $2.47 Million Stock Holdings in Gilead Sciences, Inc. (NASDAQ:GILD)

Intrust Bank NA raised its stake in Gilead Sciences, Inc. (NASDAQ:GILD) by 10.0% during the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 26,764 shares of the biopharmaceutical company’s stock after buying an additional 2,435 shares during the quarter. Intrust Bank NA’s holdings in Gilead Sciences were worth $2,472,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds also recently made changes to their positions in GILD. HHM Wealth Advisors LLC boosted its stake in Gilead Sciences by 118.5% in the 4th quarter. HHM Wealth Advisors LLC now owns 284 shares of the biopharmaceutical company’s stock worth $26,000 after purchasing an additional 154 shares during the period. YANKCOM Partnership bought a new stake in shares of Gilead Sciences in the fourth quarter valued at about $28,000. Decker Retirement Planning Inc. acquired a new position in shares of Gilead Sciences during the fourth quarter worth about $29,000. Crews Bank & Trust bought a new position in shares of Gilead Sciences during the fourth quarter worth about $31,000. Finally, Stephens Consulting LLC lifted its stake in Gilead Sciences by 325.0% in the 4th quarter. Stephens Consulting LLC now owns 340 shares of the biopharmaceutical company’s stock valued at $31,000 after acquiring an additional 260 shares in the last quarter. Institutional investors and hedge funds own 83.67% of the company’s stock.

Analysts Set New Price Targets

A number of research firms have recently issued reports on GILD. Morgan Stanley lifted their price objective on shares of Gilead Sciences from $123.00 to $130.00 and gave the company an “overweight” rating in a report on Tuesday, March 11th. Wells Fargo & Company increased their price objective on shares of Gilead Sciences from $120.00 to $140.00 and gave the stock an “overweight” rating in a research note on Wednesday, March 5th. Needham & Company LLC reaffirmed a “hold” rating on shares of Gilead Sciences in a research report on Wednesday, February 12th. Deutsche Bank Aktiengesellschaft upgraded Gilead Sciences from a “hold” rating to a “buy” rating and upped their target price for the stock from $80.00 to $120.00 in a report on Tuesday, February 18th. Finally, Piper Sandler boosted their price target on Gilead Sciences from $105.00 to $110.00 and gave the stock an “overweight” rating in a research report on Wednesday, February 12th. Eleven investment analysts have rated the stock with a hold rating, fifteen have assigned a buy rating and four have given a strong buy rating to the company’s stock. According to data from MarketBeat, Gilead Sciences currently has a consensus rating of “Moderate Buy” and a consensus target price of $105.12.

Insider Buying and Selling

In related news, CFO Andrew D. Dickinson sold 2,500 shares of Gilead Sciences stock in a transaction that occurred on Wednesday, January 15th. The shares were sold at an average price of $91.35, for a total transaction of $228,375.00. Following the sale, the chief financial officer now directly owns 129,873 shares of the company’s stock, valued at approximately $11,863,898.55. The trade was a 1.89 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Insiders sold a total of 302,785 shares of company stock worth $30,503,250 in the last ninety days. 0.16% of the stock is owned by insiders.

Gilead Sciences Stock Up 0.6 %

Shares of NASDAQ GILD opened at $111.79 on Friday. Gilead Sciences, Inc. has a 52 week low of $62.07 and a 52 week high of $119.96. The stock’s fifty day moving average is $105.48 and its 200 day moving average is $94.81. The company has a debt-to-equity ratio of 1.24, a quick ratio of 1.20 and a current ratio of 1.50. The stock has a market capitalization of $139.22 billion, a P/E ratio of 302.14, a PEG ratio of 0.71 and a beta of 0.21.

Gilead Sciences (NASDAQ:GILD) last released its earnings results on Tuesday, February 11th. The biopharmaceutical company reported $1.90 EPS for the quarter, beating the consensus estimate of $1.67 by $0.23. Gilead Sciences had a net margin of 1.67% and a return on equity of 31.63%. Sell-side analysts forecast that Gilead Sciences, Inc. will post 7.95 earnings per share for the current fiscal year.

Gilead Sciences Increases Dividend

The firm also recently declared a quarterly dividend, which was paid on Friday, March 28th. Stockholders of record on Friday, March 14th were paid a $0.79 dividend. This is a positive change from Gilead Sciences’s previous quarterly dividend of $0.77. The ex-dividend date was Friday, March 14th. This represents a $3.16 annualized dividend and a dividend yield of 2.83%. Gilead Sciences’s dividend payout ratio (DPR) is presently 854.05%.

About Gilead Sciences

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.